Current disease status-Recurrent cancer - Page 4 of 19 Posts on Medivizor
Navigation Menu

Current disease status-Recurrent cancer Posts on Medivizor

Pembrolizumab improves stage 3 melanoma outcomes

Posted by on Jun 4, 2018 in Melanoma | 0 comments

In a nutshell This study investigated the effectiveness of pembrolizumab (Keytruda) in the treatment of patients with stage 3 melanoma who underwent surgery. Researchers suggested that this drug is associated with longer recurrence-free survival with no new side effects. Some background The use of PD-1 antibodies, such as pembrolizumab, in patients...

Read More

Comparing two targeted therapy drugs – is gefitinib safer than erlotinib?

Posted by on May 21, 2018 in Lung cancer | 0 comments

In a nutshell This study compared two targeted therapy drugs gefitinib (Iressa) and erlotinib (Tarceva) in terms of effectiveness and safety at treating patients with advanced non-small-cell lung cancer. They concluded gefitinib was as effective as erlotinib but with fewer toxic side effects. Some background Current and newer treatment options...

Read More

Is targeted therapy better at treating advanced NSCLC than current chemotherapy treatment?

Posted by on Apr 21, 2018 in Lung cancer | 0 comments

In a nutshell This study examined the effectiveness of the targeted therapy drug nivolumab (Opdivo) at treating advanced non-small-cell lung cancer, particularly for patients with cancer that has spread to the liver. The authors concluded that nivolumab led to an improved overall survival compared to chemotherapy for these patients. Some background...

Read More

Treating types of non-small-cell lung cancer with nedaplatin chemotherapy

Posted by on Jan 17, 2018 in Lung cancer | 0 comments

In a nutshell This study looked at the effectiveness of the chemotherapy drug nedaplatin (Aqupla) to treat specific types of non-small-cell lung cancer (NSCLC). The authors concluded that nedaplatin was effective at treating patients with squamous cell lung cancer. Some background Targeted therapy has improved the outcome of certain types of NSCLC...

Read More

Looking for patients with advanced squamous cell non-small-cell lung cancer or head and neck squamous cell carcinoma to test a new type of immunotherapy

Posted by on Dec 20, 2017 in Lung cancer | 0 comments

In a nutshell This phase 1 trial is examining the safety and effectiveness of a new type of immunotherapy. The treatment involves genetically enhancing patients’ own immune cells to better fight advanced non-small-cell lung cancer (NSCLC) or head and neck cancer. The main outcome to be measured will be the highest safe dose of the treatment. This...

Read More

Comparing targeted therapies for patients with advanced non-small-cell lung cancer

Posted by on Dec 16, 2017 in Lung cancer | 0 comments

In a nutshell The authors aimed to understand the effectiveness of anti-PD-L1 therapy in patients with previously treated non-small-cell lung cancer (NSCLC) compared to current treatments. The authors concluded that anti-PD-L1 therapy could be more beneficial than the chemotherapy drug docetaxel (Taxotere) at treating patients with previously treated...

Read More

Searching for stage I-III breast cancer patients to test omega-3 supplementation

Posted by on Dec 6, 2017 in Breast cancer | 0 comments

In a nutshell This trial aims to evaluate the use of omega-3 fatty acid supplements to prevent side effects caused by aromatase inhibitors. Aromatase inhibitors can cause arthralgia (bone and joint pain). The main outcomes to be investigated are the change in pain score and the change in joint symptoms. This trial is taking place in Cleveland and...

Read More

Nivolumab treatment is associated with an improved survival in advanced melanoma

Posted by on Oct 16, 2017 in Melanoma | 0 comments

In a nutshell This study investigated the effect of nivolumab (Opdivo) in patients with progressive melanoma after ipilimumab (Yervoy) treatment. Researchers suggested that nivolumab treatment is associated with better response compared with chemotherapy. Some background Recent new therapies, such as immunotherapy, have changed the treatment of...

Read More

Looking for patients with advanced non-small cell lung cancer to test the effectiveness of Poziotinib

Posted by on Sep 26, 2017 in Lung cancer | 0 comments

In a nutshell This phase 2 clinical trial will test the effectiveness of poziotinib in treating locally advanced (spread to nearby tissue) or metastatic (spread to other parts of the body) non-small cell lung cancer (NSCLC) with an EGFR mutation. The primary outcome will be measured by the response rate to the treatment. This trial is being conducted...

Read More